Genesis Research and Development Halts Operations Amid Cash Shortfall
May 06, 2010
Genesis Research and Development Halts Operations Amid Cash Shortfall
Work on single-stranded RNAi technology that Genesis had been conducting for its subsidiary Solirna Biosciences has also ceased, although it may restart if an existing investor provides additional financing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genesis Research and Development Proposes Stock Purchase Plan to Fund ssRNAi Subsidiary
February 18, 2010 / Gene Silencing News - Genesis Shareholders OK Spinout of Company ssRNAi Assets into New Firm
October 29, 2009 / Gene Silencing News - As Shareholder Vote Looms, Genesis Provides New Details on ssRNAi Subsidiary
October 15, 2009 / Gene Silencing News - Genesis R&D Inks Deal to Sell 7.4M Shares of Stock
June 17, 2010 / Gene Silencing News - Genesis Receives Funding Commitment for New Subsidiary, Prepares New Share-Purchase Plan
July 9, 2009 / Gene Silencing News